diplomsko delo univerzitetnega študijskega programa I. stopnje
Lara Metlika (Avtor), Uroš Potočnik (Mentor), Boris Gole (Komentor)

Povzetek

Eno izmed obetavnejših bioloških zdravil za zdravljenje kronične vnetne bolezni je biološko zdravilo vedolizumab. Na žalost je neodziv na terapijo še vedno prisoten pri 1/3 bolnikov. Natančna napoved odzivnosti pred začetkom terapije bi bila zato zelo pomembna. V diplomskem delu je prikazan sistematski pregled literature. Iskanje PubMed je bilo izvedeno z vnaprej določenimi ključnimi besedami in izrazi, da se ugotovijo ustrezne študije o napovedovalcih odziva. V rezultatih so prikazani dobljeni tipi markerjev; proteinski, klinični, v povezavi z koncentracijo ter na ravni mRNA, ter medsebojne primerjave različnih vrednosti. Bolniki s hudo boleznijo ali predhodno izpostavljenostjo anti-TNF terapiji se manj verjetno odzovejo na vedolizumab. Prav tako so zanimivi proteinski markerji C-reaktiven protein, raven albumina ter fekalnega kalprotektina. Zaključimo, da je v prihodnje potrebnih še več študij ter bolj sistematičen pristop k iskanju biomarkerjev.

Ključne besede

kronična vnetna črevesna bolezen;Crohnova bolezen;ulcerozni kolitis;vedolizumab;odziv;napovedovalci odziva;diplomske naloge;

Podatki

Jezik: Slovenski jezik
Leto izida:
Tipologija: 2.11 - Diplomsko delo
Organizacija: UM FKKT - Fakulteta za kemijo in kemijsko tehnologijo
Založnik: [L. Metlika]
UDK: 615.015.1:616.34-002(043.2)
COBISS: 33448451 Povezava se bo odprla v novem oknu
Št. ogledov: 698
Št. prenosov: 54
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarni jezik: Angleški jezik
Sekundarni naslov: Biomarkers of response to vedolizumab in inflammatory bowel diseases patients
Sekundarni povzetek: Vedolizumab represents one of the most promising biological medications used in the chronic inflammatory disease treatment. Unfortunately, 1/3 of the patients are still classified as non-responsive to the vedolizumab therapy. Therefore, it would be extremely important to determine the precise level of responsiveness before starting the therapy. The present diploma thesis examines a systematic literature review. PubMed search was carried out by means of the pre-defined key words and expressions in order to establish the relevant studies on predictors of response. The results show the types of markers obtained in various studies: protein markers, clinical markers, markers related to the vedolizumab concentration, and markers on mRNA level. The results also illustrate the comparison between different marker values which were given in different scientific articles. Patients with mild form of the disease and anti-TNF naive patients are more likely to respond to the vedolizumab therapy. The following protein markers have also proved to be very interesting: C-reactive protein as well as the levels of albumin and faecal calprotectin. In the end it can be concluded that further research as well as a more systematic approach to finding biomarkers are needed in the future.
Sekundarne ključne besede: Chronic inflammatory bowel disease;Crohn's disease;ulcerative colitis;vedolizumab;response;and predictors of response.;
Vrsta dela (COBISS): Diplomsko delo/naloga
Komentar na gradivo: Univ. v Mariboru, Fak. za kemijo in kemijsko tehnologijo
Strani: X, 43 str.
ID: 11987062